Süleyman Yazıcı, Osman Fehmi Beyazal, Hasan Tezcan
{"title":"哪种疫苗更有利于降低深静脉血栓形成的风险，CoronaVac、BNT162b2还是TURKOVAC？","authors":"Süleyman Yazıcı, Osman Fehmi Beyazal, Hasan Tezcan","doi":"10.1177/00368504251366362","DOIUrl":null,"url":null,"abstract":"<p><p>ObjectiveThe aim of this study is to reveal the relationship between TURKOVAC, CoronaVac, and BNT162b2 and deep vein thrombosis.MethodsBetween 2022 and 2024, a case-control study was planned with 400 patients included (deep vein thrombosis group (<i>n</i> = 200) and control group (<i>n</i> = 200). Patients were divided into four groups according to their vaccine types. Group 1 (<i>n</i> = 54): those who received only CoronaVac, Group 2 (<i>n</i> = 233): those who received only BNT162b2, Group 3 (<i>n</i> = 49): those who received CoronaVac for the first dose, and then BNT162b2, Group 4 (<i>n</i> = 15): those who received BNT162b2 for the first dose and then TURKOVAC. First, the deep vein thrombosis and control groups were compared regarding basic characteristics. Then, patients in the four groups were compared in terms of deep vein thrombosis.ResultsNo difference was found in the frequency of COVID-19 disease in the deep vein thrombosis and control groups. The frequency of vaccination was lower in the deep vein thrombosis group (84%-91.5%). According to the multivariate regression test result, we found that COVID-19 vaccination was protective against deep vein thrombosis (<i>p</i> = 0.003, OR = 0.377 [95% CI, 0.197-0.722]). After being divided into four groups, the rates of deep vein thrombosis were 36 (66.7%), 96 (41.2%), 29 (59.2%), and 7 (46.7%), respectively. The frequency of deep vein thrombosis was significantly lower in Group 2 (<i>p</i> = 0.003). Although no statistically significant difference was found among other groups, the lowest deep vein thrombosis frequency was found in Group 4, Group 3, and Group 1, respectively.ConclusionThe frequency of COVID-19 vaccination was lower in patients with deep vein thrombosis than in those without. Deep vein thrombosis was least common in patients who received only BNT162b2. Although the frequency of deep vein thrombosis was similar in the groups, we found that the lowest rate of deep vein thrombosis was in the group that received TURKOVAC after BNT162b2.</p>","PeriodicalId":56061,"journal":{"name":"Science Progress","volume":"108 3","pages":"368504251366362"},"PeriodicalIF":2.9000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12340335/pdf/","citationCount":"0","resultStr":"{\"title\":\"Which type of vaccine is more beneficial for reducing the risk of deep vein thrombosis, CoronaVac, BNT162b2, or TURKOVAC?\",\"authors\":\"Süleyman Yazıcı, Osman Fehmi Beyazal, Hasan Tezcan\",\"doi\":\"10.1177/00368504251366362\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>ObjectiveThe aim of this study is to reveal the relationship between TURKOVAC, CoronaVac, and BNT162b2 and deep vein thrombosis.MethodsBetween 2022 and 2024, a case-control study was planned with 400 patients included (deep vein thrombosis group (<i>n</i> = 200) and control group (<i>n</i> = 200). Patients were divided into four groups according to their vaccine types. Group 1 (<i>n</i> = 54): those who received only CoronaVac, Group 2 (<i>n</i> = 233): those who received only BNT162b2, Group 3 (<i>n</i> = 49): those who received CoronaVac for the first dose, and then BNT162b2, Group 4 (<i>n</i> = 15): those who received BNT162b2 for the first dose and then TURKOVAC. First, the deep vein thrombosis and control groups were compared regarding basic characteristics. Then, patients in the four groups were compared in terms of deep vein thrombosis.ResultsNo difference was found in the frequency of COVID-19 disease in the deep vein thrombosis and control groups. The frequency of vaccination was lower in the deep vein thrombosis group (84%-91.5%). According to the multivariate regression test result, we found that COVID-19 vaccination was protective against deep vein thrombosis (<i>p</i> = 0.003, OR = 0.377 [95% CI, 0.197-0.722]). After being divided into four groups, the rates of deep vein thrombosis were 36 (66.7%), 96 (41.2%), 29 (59.2%), and 7 (46.7%), respectively. The frequency of deep vein thrombosis was significantly lower in Group 2 (<i>p</i> = 0.003). Although no statistically significant difference was found among other groups, the lowest deep vein thrombosis frequency was found in Group 4, Group 3, and Group 1, respectively.ConclusionThe frequency of COVID-19 vaccination was lower in patients with deep vein thrombosis than in those without. Deep vein thrombosis was least common in patients who received only BNT162b2. Although the frequency of deep vein thrombosis was similar in the groups, we found that the lowest rate of deep vein thrombosis was in the group that received TURKOVAC after BNT162b2.</p>\",\"PeriodicalId\":56061,\"journal\":{\"name\":\"Science Progress\",\"volume\":\"108 3\",\"pages\":\"368504251366362\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12340335/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Science Progress\",\"FirstCategoryId\":\"103\",\"ListUrlMain\":\"https://doi.org/10.1177/00368504251366362\",\"RegionNum\":4,\"RegionCategory\":\"综合性期刊\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/10 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"MULTIDISCIPLINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Science Progress","FirstCategoryId":"103","ListUrlMain":"https://doi.org/10.1177/00368504251366362","RegionNum":4,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/10 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}
Which type of vaccine is more beneficial for reducing the risk of deep vein thrombosis, CoronaVac, BNT162b2, or TURKOVAC?
ObjectiveThe aim of this study is to reveal the relationship between TURKOVAC, CoronaVac, and BNT162b2 and deep vein thrombosis.MethodsBetween 2022 and 2024, a case-control study was planned with 400 patients included (deep vein thrombosis group (n = 200) and control group (n = 200). Patients were divided into four groups according to their vaccine types. Group 1 (n = 54): those who received only CoronaVac, Group 2 (n = 233): those who received only BNT162b2, Group 3 (n = 49): those who received CoronaVac for the first dose, and then BNT162b2, Group 4 (n = 15): those who received BNT162b2 for the first dose and then TURKOVAC. First, the deep vein thrombosis and control groups were compared regarding basic characteristics. Then, patients in the four groups were compared in terms of deep vein thrombosis.ResultsNo difference was found in the frequency of COVID-19 disease in the deep vein thrombosis and control groups. The frequency of vaccination was lower in the deep vein thrombosis group (84%-91.5%). According to the multivariate regression test result, we found that COVID-19 vaccination was protective against deep vein thrombosis (p = 0.003, OR = 0.377 [95% CI, 0.197-0.722]). After being divided into four groups, the rates of deep vein thrombosis were 36 (66.7%), 96 (41.2%), 29 (59.2%), and 7 (46.7%), respectively. The frequency of deep vein thrombosis was significantly lower in Group 2 (p = 0.003). Although no statistically significant difference was found among other groups, the lowest deep vein thrombosis frequency was found in Group 4, Group 3, and Group 1, respectively.ConclusionThe frequency of COVID-19 vaccination was lower in patients with deep vein thrombosis than in those without. Deep vein thrombosis was least common in patients who received only BNT162b2. Although the frequency of deep vein thrombosis was similar in the groups, we found that the lowest rate of deep vein thrombosis was in the group that received TURKOVAC after BNT162b2.
期刊介绍：
Science Progress has for over 100 years been a highly regarded review publication in science, technology and medicine. Its objective is to excite the readers'' interest in areas with which they may not be fully familiar but which could facilitate their interest, or even activity, in a cognate field.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
